Aminoglycosides are used to treat aerobic gram-negative infections and can be administered with other antibiotics to treat resistant gram-positive infections. Aminoglycosides are most often administered topically or parenterally. During the surgical period, surgeons may use aminoglycosides to irrigate wounds or may apply them directly to surgical incisions. Because aminoglycosides are excreted almost exclusively via the renal system, health care providers must carefully consider the patient's renal function before selecting these medications for treatment. Aminoglycosides can produce several significant adverse effects, including nephrotoxicity and ototoxicity. Perioperative nurses should familiarize themselves with aminoglycosides, particularly focusing on dosage, monitoring requirements, and effects in special populations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.aorn.2010.09.030 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Role of Nasal Microbiota and Sensitivity in Patients With Chronic Rhinosinusitis at a Rural Tertiary Care Hospital.
Cureus
December 2024
Department of Otolaryngology, Head and Neck Surgery, Sri Devaraj Urs Academy of Higher Education and Research, Kolar, IND.
Background and aim Etiopathogeneses of chronic rhinosinusitis are poorly understood. Recent research emphasizes culture-independent molecular sequencing to identify clusters of flora that may function as drivers of inflammation. Studies also indicate that macrolides are as effective as corticosteroids in controlling chronic rhinosinusitis.
View Article and Find Full Text PDFNetwork Pharmacology Combined With Metabolomics Reveals the Mechanism of Yangxuerongjin Pill Against Type 2 Diabetic Peripheral Neuropathy in Rats.
Drug Des Devel Ther
January 2025
Beijing Tongrentang Technology Development Co., Ltd. Pharmaceutical Factory, Beijing, 100079, People's Republic of China.
Purpose: This study aims to explore the mechanism of Yangxuerongjin pill (YXRJP) in the treatment of diabetic peripheral neuropathy (DPN) by network pharmacology and metabolomics technology combined with animal experiments, and to provide scientific basis for the treatment of DPN.
Methods: In this study, network pharmacology analysis was applied to identify the active compounds, core targets and signal pathways, which might be responsible for the effect of DPN. The DPN model was established by high-fat diet combined with streptozotocin (STZ) injection, and the rats were given administration for 12 weeks.
The clinical observation of none-promyelocytic AML patients inducted with idarubicin or daunorubicin included standard regimens: a tertiary care center experience.
BMC Pharmacol Toxicol
January 2025
Department of Hematology, Zhujiang Hospital of Southern Medical University, No. 253, Gongye Road, Haizhu District, Guangzhou, 510280, China.
Background: Few Chinese study compared the impacts of idarubicin and daunorubicin based "3+7" intensive chemotherapies on early and long-term outcomes of AML patients through exploring their real-world data.
Patients And Methods: Our none promyelocytic AML patients inducted with "3+7" regimens were studied to find out the factors relating with induction response and long term survival.
Results: Idarubicin induction was related with less chemotherapy refractory rate comparing with daunorubicin induction (10% vs 25%, P = 0.
Combination therapy versus monotherapy: retrospective analysis of antibiotic treatment of enterococcal endocarditis.
BMC Infect Dis
January 2025
Medical Microbiology, Leeds Teaching Hospitals Trust, Leeds, UK.
Background: Guidelines suggest treating fully penicillin-susceptible Enterococcus faecalis strains causing infective endocarditis with amoxicillin combined with gentamicin or ceftriaxone, but clinical evidence to support this practice is limited and monotherapy cohorts were excluded from studies. We describe antibiotic treatment, complications, and outcomes in patients with Enterococcus faecalis infective endocarditis, specifically comparing monotherapy versus combination therapy.
Methods: Retrospective analysis of prospectively collected cohort of patients with definite or possible infective endocarditis from 2 English centres between 2006 and 2021.
Is first-line treatment with polatuzumab vedotin-rituximab-cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model.
BMJ Open
January 2025
Department of Pharmacy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, People's Republic of China
Objective: To evaluate the cost-effectiveness of polatuzumab vedotin-rituximab-cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) in CD20-positive patients with previously untreated diffuse large B-cell lymphoma (DLBCL) in China.
Design: A Markov model was constructed to analyse the cost-effectiveness of two strategies in CD20-positive patients with previously untreated DLBCL over a lifetime horizon: (1) pola-R-CHP and (2) rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). The clinical outcomes were obtained from the POLARIX(NCT03274492), SCHOLAR-1, ZUMA-7(NCT03391466) and TRANSFORM(NCT03575351) trials.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!